Pineridge Advisors’s Medifast MED Stock Holding History

Pineridge Advisors’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-132	Closed	-$5.04K	–	653
2024 Q1	$5.04K	Hold	132	–	–	﹤0.01%	360
2023 Q4	$8.84K	Buy	+132	New	+$9.2K	﹤0.01%	399

Other funds holding MED

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Pineridge Advisors's MED Position: Q2 2024 in Review

Pineridge Advisors sold out of Medifast (MED) in Q2 2024, closing a stake of 132 shares — an estimated $5.04K sold.

Pineridge Advisors first reported a position in MED in Q4 2023 and held it in 2 quarters. The position peaked at $8.84K in Q4 2023. 158 funds tracked by Wall St. Rank hold MED as of Q2 2024.

Pineridge Advisors reported no remaining Medifast position as of Q2 2024 after selling out during the quarter.
Pineridge Advisors sold 132 Medifast shares in Q2 2024, an estimated $5.04K.
Pineridge Advisors first reported a position in Medifast in Q4 2023 and held it in 2 quarters.
Pineridge Advisors's Medifast position peaked at $8.84K in Q4 2023.
158 funds tracked by Wall St. Rank held Medifast as of Q2 2024.

Based on Pineridge Advisors's 13F filing for Q2 2024, filed 25 Jul 2024.